CD56 Positive Intestinal T-Cell Lymphoma: Treatment with High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation.

スポンサーリンク

概要

• 論文の詳細を見る

• A 63-year-old man presented with a perforation of the small intestine. A diagnosis of intestinal T-cell lymphoma (ITCL) was made from CD (cluster differentiation) 3 positivity and a rearrangement of T-cell receptor genes. The tumor also expressed CD56, which suggests it belongs to a rare subtype derived from activated cytotoxic intraepithelial T lymphocytes. Although the prognosis of ITCL has been considered to be very poor irrespective of CD56 positivity, complete remission was achieved in this case by high dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) even after relapse. Auto-PBSCT in the earlier stage of the disease might improve the prognosis.(Internal Medicine 41: 734-737, 2002)

• 社団法人　日本内科学会の論文

著者

• Kameoka Junichi

  The Department Of Rheumatology And Hematology Tohoku University School Of Medicine

• Tateno Hiroo

  The Department Of Pathology Miyagi Cancer

• NOMURA Jun

  the Department of Internal Medicine Miyagi Cancer Center

• SASAKI Takeshi

  the Department of Rheumatology and Hematology, Tohoku University School of Medicine

• Sasaki Takeshi

  The Department Of Rheumatology And Hematology Tohoku University School Of Medicine

• Okuda Mitsutaka

  the Department of Internal Medicine Miyagi Cancer Center

• OKUDA Mitsutaka

  The Department of Internal Medicine, Miyagi Cancer Center

• TATENO Hiroo

  The Department of Pathology, Miyagi Cancer Center

関連論文

• CD56 Positive Intestinal T-Cell Lymphoma : Treatment with High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation
• CD56 Positive Intestinal T-Cell Lymphoma: Treatment with High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation.

スポンサーリンク